Drug Discovery Weekly — April 8, 2026

FDA & Regulatory Decisions

1. FDA Single-Trial Approval Policy Takes Effect FDA officials Vinay Prasad, MD, MPH, and Martin Makary, MD, MPH published a formal commentary confirming that the agency will now require only one pivotal study — rather than the traditional two — to approve new drugs under certain conditions. The shift, aimed at speeding the approval process without sacrificing scientific rigor, marks one of the most consequential structural changes to the U.S. drug review framework in a generation. Proponents argue it rewards mechanistically compelling, well-designed trials; critics warn it introduces additional uncertainty around reproducibility of results.

2. Q1 2026 Hepatology Approvals Recap: MASH, Gene Editing, and Pruritus HCPLive's Q1 2026 hepatology recap, published this morning, highlights major advances that cleared or advanced through FDA review in the first quarter, including the first approved therapy for pruritus in primary biliary cholangitis (PBC), progress in metabolic-associated steatohepatitis (MASH), hepatitis B, and gene editing for alpha-1 antitrypsin deficiency. These clearances signal an accelerating regulatory cadence in liver disease, an area long starved of meaningful approved options.

3. Q2 2026 FDA Decision Calendar: Seven Key Oncology Reviews in Focus Targeted Oncology's updated guide to Q2 2026 decisions — published two days ago — highlights seven upcoming FDA actions in oncology, with Dato-DXd (datopotamab deruxtecan) in triple-negative breast cancer and Orca-T in blood cancers among the most closely watched. Both carry the potential to meaningfully alter survival outcomes and advance precision oncology care in their respective indications.

Clinical Trial Spotlight

1. Amgen Phase 3 TEPEZZA OBI: 77% Proptosis Response Rate in Thyroid Eye Disease Amgen announced positive topline results from the Phase 3 TEPEZZA OBI trial of a subcutaneous formulation of teprotumumab (Tepezza) in adults with moderate-to-severe active thyroid eye disease (TED). The trial met its primary endpoint: the subcutaneous administration achieved a statistically significant and clinically meaningful 77% proptosis response rate (76.7% TEPEZZA OBI vs. placebo) during the 24-week placebo-controlled period. The original intravenous Tepezza was approved for TED, but a subcutaneous formulation could dramatically improve convenience and patient adherence — potentially expanding real-world uptake of a drug already considered standard of care.

2. Key Neurology Trial Readouts: Early 2026 Watch List NeurologyLive's freshly published guide (this morning) to key neurology trial readouts in early 2026 identifies a pipeline of pivotal data expected across cognitive decline and neurodegeneration. Among the signals highlighted: a trial utilizing the Clinical Dementia Rating-Sum of Boxes (CDR-SB) as a primary endpoint, with a reported baseline mean score of 3.45 (± 1.70), reflecting a mild-to-moderate Alzheimer's population. These readouts are being closely watched for their potential to define the next generation of CNS therapies beyond the current anti-amyloid wave.

3. Karyopharm Phase 3 SENTRY: Mixed Results in Myelofibrosis Karyopharm Therapeutics reported (March 24) that the Phase 3 SENTRY trial of selinexor in myelofibrosis met its first co-primary endpoint, demonstrating statistically significant improvement in spleen volume reduction compared to control. However, across other secondary and exploratory endpoints — including progression-free survival, hemoglobin stabilization, and bone marrow fibrosis improvement — no meaningful difference was observed between the trial arms. The mixed profile creates regulatory uncertainty: the spleen volume win may be sufficient to support an NDA submission, but the lack of broader benefit could affect label negotiations and commercial positioning in an increasingly competitive myelofibrosis market.

Deals & Pipeline Moves

1. Gilead Sciences Acquires Tubulis for $5 Billion, Deepens ADC Bet In what analysts are calling the most strategically significant ADC deal of the year, Gilead Sciences agreed to acquire German biotech Tubulis for $5 billion, announced today. Gilead and Tubulis had previously established an option and licensing agreement in 2024 valued at up to $465 million, giving Gilead access to Tubulis' proprietary antibody-drug conjugate (ADC) platforms — a relationship that has now converted into a full acquisition. The move intensifies the industry-wide race to dominate ADC technology following Pfizer's acquisition of Seagen and AstraZeneca/Daiichi Sankyo's deepening ADC partnership. Gilead's oncology strategy, which has faced criticism for underperformance, is clearly doubling down on next-generation linker-payload platforms that could differentiate it from established ADC players.

2. Neurocrine Biosciences Acquires Soleno Therapeutics for $2.9 Billion Neurocrine Biosciences — long considered a potential acquisition target itself — made its largest-ever M&A move with a $2.9 billion deal to acquire Soleno Therapeutics, as VYKAT XR (diazoxide choline) sales soar in Prader-Willi syndrome. The acquisition, announced two days ago, adds a rare disease franchise to Neurocrine's CNS-heavy portfolio and follows the company's strategy of diversifying beyond its INGREZZA (valbenazine) core. With VYKAT XR generating strong commercial momentum in a high-unmet-need orphan indication, the deal represents both an immediate revenue contribution and a platform for future rare disease pipeline build-out.

Analysis: Development of the Week

Gilead's $5B Tubulis Acquisition — Why the ADC Arms Race Just Reached a New Level

The $5 billion Gilead–Tubulis deal, announced this morning, is more than a large transaction: it represents a strategic inflection point in how Big Pharma is approaching the antibody-drug conjugate space.

The Competitive Landscape ADCs have become the hottest modality in oncology following the transformative commercial success of drugs like Enhertu (trastuzumab deruxtecan) and Trodelvy (sacituzumab govitecan). Every major oncology-focused company is now racing to secure proprietary linker-payload chemistry that can differentiate their ADC programs from the increasingly crowded field. Tubulis — a Munich-based biotech — had built a reputation for its P5 (phosphodiester) and Tub-tag conjugation platforms, which offer precise, site-specific drug attachment and improved therapeutic windows compared to first-generation ADC chemistry.

Why This Matters for Gilead Gilead's oncology strategy has been under intense scrutiny. Despite the $21 billion Immunomedics acquisition in 2020 that brought Trodelvy, the company has struggled to build a deep ADC pipeline organically. The 2024 option deal with Tubulis was widely seen as a hedge; converting it to full ownership signals Gilead's conviction that next-generation ADC chemistry will be the decisive competitive moat in oncology over the next decade.

Patient Impact If Tubulis' platforms deliver on their preclinical promise — particularly in historically difficult-to-treat solid tumors — patients could gain access to more effective and less toxic ADC regimens. The combination of Gilead's clinical development infrastructure and Tubulis' chemistry capabilities could meaningfully accelerate IND filings across multiple tumor types.

The Broader M&A Wave This deal adds to an already extraordinary run of biopharma consolidation. In the past three weeks alone, seven transactions totaling $29 billion have been announced — including Biogen/Apellis ($5.6B), BioMarin/Amicus ($4.8B), and Neurocrine/Soleno ($2.9B) — signaling that large-cap pharma is aggressively filling pipeline gaps through acquisition rather than internal R&D.

What to Watch

1. Dato-DXd PDUFA in TNBC — One of the most anticipated FDA decisions of Q2 2026, datopotamab deruxtecan's potential approval in triple-negative breast cancer would validate Daiichi Sankyo/AstraZeneca's ADC franchise and challenge Trodelvy's dominance in a difficult-to-treat indication.

2. Orca-T FDA Decision in Blood Cancers — The engineered T-cell therapy faces its pivotal FDA review this quarter, with survival outcome data that could establish a new standard of care in post-transplant settings.

3. Neurology CDR-SB Trial Primary Readout — The full dataset from the early 2026 Alzheimer's trial identified in NeurologyLive's watch list, using CDR-SB as the primary endpoint with a baseline mean of 3.45, is expected imminently. Results could inform the next wave of disease-modifying therapy filings.

4. TEPEZZA OBI NDA Filing Timeline — Following Amgen's strong Phase 3 topline data, the market will watch for the timing and scope of the subcutaneous Tepezza NDA submission, which could open a meaningful new commercial chapter for the drug and for the broader TED treatment landscape.

5. Karyopharm SENTRY Second Co-Primary Endpoint Disclosure — With the first co-primary (spleen volume reduction) already met, investors and clinicians are awaiting more detailed data on the second co-primary endpoint and quality-of-life data from SENTRY that will determine whether a regulatory filing is viable and commercially compelling.